Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Anti-MicroRNA and Prednisolone Administration Show Antileukemic Effects in Acute Lymphoblastic Leukemia Cells

The silencing of microRNAs associated with ALL demonstrated antileukemic effects in leukemic cell lines and appeared to enhance the effect of prednisolone treatment. 

Hematology Advisor
CCND3 is Indispensable for the Maintenance of B-Cell Acute Lymphoblastic Leukemia

Researchers demonstrated that CCND3 is essential for the proliferation and survival of B-ALL, independent of the mutational background.

Inotuzumab Ozogamicin Deemed Effective in Heavily Pretreated B-ALL

Inotuzumab Ozogamicin provides a bridge to cellular therapy in children and adolescents with CD22-positive R/R B-ALL. 

Cancer Therapy Advisor

Haploidentical vs Sibling, Unrelated, or Cord Blood Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Scientists perform a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. 

Blood Advances
Survival Rate Rises Steadily Among Patients With Relapsed ALL After Stem Cell Transplant

The 2-year OS rate nearly doubled during the past 2 decades among patients with Ph+ALL who relapsed after allogeneic hematopoietic stem cell transplantation. 

Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission

Researchers conducted a prospective study to investigate the role of CAR-T therapy in patients with persistent/recurrent MRD-positive ALL in first remission.

Frontiers in Immunology
Differential mRNA and Long Noncoding RNA Expression Profiles in Pediatric B-Cell Acute Lymphoblastic Leukemia Patients

Researchers determine the potential roles of lncRNAs involved in pathogenesis of B-ALL by analyzing the expression profile of lncRNAs and mRNAs in B-ALL, respectively.

BMC Pediatrics
DNA Sequencing to Predict Leukemia Relapse After CAR-T Therapy

An international team of researchers identified biomarkers that nearly always can predict which patients with ALL will relapse or need further treatment within months... 

Oncology Times - Latest Articles
Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Debulking pre-treatment enhanced responses to blinatumomab compared to historic studies, indicating that this strategy may help to improve outcomes for R/R B-ALL patients.


Frontiers in Oncology
Aberrant RNA Splicing Events in Acute Lymphoblastic Leukemia Underlies Resistance to Immunotherapy

Aberrant splicing of CD22 leads to downregulation of this protein in pediatric B-ALL, rendering malignant cells resistant to the effects of CD22-directed immunotherapies. 

Medical Xpress
Pretreatment Disease Burden and Outcomes With Commercial Tisagenlecleucel in Pediatric/Young Adult B-Cell Acute Lymphoblastic Leukemia

Pretreatment high disease burden was associated with poorer outcomes in pediatric and young adult patients who received commercial tisagenlecleucel for R/R B-cell ALL.

The ASCO Post
TCR-haplo-HSCT With ATG May Yield Response in Patients With Relapsed/Refractory BCR-ALL

Among adolescent and pediatric patients with R/R BCP-ALL, TCR-haplo-HSCT with low-dose ATG may improve outcomes, according to research published in Frontiers in Pediatrics.

Hematology Advisor
Reinfusion of CAR-T Cells May Prevent Relapse in Acute Lymphoblastic Leukemia

Reinfusion of CAR T-cell therapy may reduce the risk of relapse in children and young adults with B-cell ALL, according to research presented at the 2021 ASH Annual Meeting.

Cancer Therapy Advisor
Patients With Blood Cancer at Greater Risk for Severe Breakthrough COVID-19 Infection

Patients with blood cancer appeared at greater risk for severe and life-threatening COVID-19 illness than healthy individuals and did not always achieve optimal protection from vaccination.

Extracellular Vesicles Carrying miRNA-181b-5p Affects the Malignant Progression of Acute Lymphoblastic Leukemia

This study investigated how serum extracellular vesicles-carried miRNA-181b-5p affected the proliferation, cell cycle and apoptosis of acute lymphoblastic leukemia cells.

Journal of Translational Medicine
Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor ALL

Recently, the CD19-directed CAR T-cell therapy brexucabtagene autoleucel was approved for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The ASCO Post
Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia

Study investigators evaluated SF2535, a novel small molecule inhibitor of PI3Kδ and BRD4, in B-ALL. 

Frontiers in Oncology

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb(11, 160, 224)
rgb(245, 111, 66)
rgb (245, 152, 2)
rgb(164, 116, 173)
rgb(219, 105, 96)
rgb(66, 135, 245)
rgb(169, 196, 201)
rgb(125, 127, 130)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rgb((217, 11, 193)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(107, 129, 201)
rgb (214, 104, 96)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
rgb(214, 139, 202)